- Investing.com
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company’s drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. It develops clinical programs, including Barzolvolimab (CDX-0159), a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity for treating chronic urticarias, prurigo nodularis, eosinophilic esophagitis, and atopic dermatitis; and CDX-622, a bispecific candidate for inflammatory diseases, which targets two complementary pathways that drive chronic inflammation, potently neutralizing the alarmin thymic stromal lymphopoietin and depleting mast cells through stem cell factor starvation. Celldex Therapeutics, Inc. is headquartered in Hampton, New Jersey.
Financial Strength | With $673 million in cash, Celldex is well-funded through 2027, supporting clinical programs and potential commercialization efforts |
Market Positioning | Analyst targets range from $30 to $90, with barzolvolimab poised to compete against established treatments like Xolair in the lucrative CSU market |
Pipeline Expansion | Delve into CDX-622, Celldex's bispecific program targeting TSLP and SCF, opening new frontiers in asthma and food allergy treatment |
Barzolvolimab's Promise | Explore Celldex's lead candidate barzolvolimab, showing remarkable efficacy in treating chronic spontaneous urticaria with potential for $1 billion peak sales |
Metrics to compare | CLDX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipCLDXPeersSector | |
|---|---|---|---|---|
P/E Ratio | −10.3x | −2.5x | −0.5x | |
PEG Ratio | 0.18 | −0.08 | 0.00 | |
Price / Book | 5.0x | 2.5x | 2.6x | |
Price / LTM Sales | 1,720.1x | 10.3x | 3.2x | |
Upside (Analyst Target) | 40.1% | 279.6% | 45.7% | |
Fair Value Upside | Unlock | 7.1% | 4.8% | Unlock |